Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Pharmacokinetics, and Anti-viral Effects of Galidesivir Administered Via Intravenous Infusion to Subjects With Yellow Fever or COVID-19

Next Previous
Search
Trial Profile

A Phase 1b Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Pharmacokinetics, and Anti-viral Effects of Galidesivir Administered Via Intravenous Infusion to Subjects With Yellow Fever or COVID-19

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 31 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Galidesivir (Primary)
  • Indications COVID 2019 infections; Yellow fever
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors BioCryst Pharmaceuticals

    • Most Recent Events

    • 25 May 2021 Status changed from recruiting to discontinued.
    • 22 Dec 2020 Results (n=24) from the part 1 of the study presented in a BioCryst Pharmaceuticals media release.
    • 05 Nov 2020 According to a BioCryst Pharmaceuticals media release, Part 1 of the trial has has completed enrollment and the company expects to report results in the fourth quarter of 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top